Twenty-two patients with small-cell carcinoma of the lung who had failed combination chemotherapy were treated with VP-16-213 as a single agent. A partial remission was achieved in one patient. Twenty-three percent of the patients experienced arrest of disease for a median of 31 weeks. Leukopenia was a major complicating side effect.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Clinical Trials|
|State||Published - 1981|
ASJC Scopus subject areas